• Home
  • About
    • Board of Directors
    • Technical Advisory Board
    • Leadership
    • Our Team
    • Partners
  • Our Programs
    • Current Programs
    • Completed Programs
  • News
    • COVID-19
  • Get Involved
  • Careers
  • Resources
  • Contact

MATRIX

  • Home
  • Current Programs
  • MATRIX
AHISA
22nd April 2019

Microbicide Research and Development (R&D) to Advance HIV Prevention Technologies through Responsive Innovation and eXcellence (MATRIX) is a five-year cooperative agreement with USAID to develop a range of feasible products (acceptable, affordable, scalable, and deliverable) to meet the unmet needs of women at risk of HIV. This ambitious and highly innovative program is led by the Magee-Women’s Research Institute at the University of Pittsburgh and the project brings together 19 partner organizations from Sub-Saharan Africa and North America, with expertise in product development, clinical trials, social and behavioral research and market and business case development.

The MATRIX collaborative includes several activity hubs to support product developers in on-boarding new products or mitigating unanticipated technical challenges; to provide end-user and stakeholder feedback on modifiable attributes of the product, its value proposition and market segments; to develop business cases, investor linkages and analytics and provide opportunities throughout the collaborative for tailored mentorship and training.

PZAT is a member of the MATRIX Consortium and falls under the Design 2 Delivery (D2D) hub which is a product neutral consultative working group using an adaptive integrated model with innovative Socio-Behavioral Research (SBR).

Mission

MATRIX seeks to develop a range of HIV prevention products that are acceptable, affordable, scalable, and deliverable by providing a platform for efficient, benchmark-driven portfolio management. MATRIX brings together organizations engaged with early-stage research and development (R&D) on novel HIV prevention products, investigators, and partners from the United States (US), Kenya, South Africa (SA), and Zimbabwe.

Objectives

  1. To enhance awareness of the evolving HIV prevention landscape and understanding of HIV prevention product development; end-user, SBR and stakeholder engagement findings among MATRIX partners.
  2. To establish a “rapid response network” (RRN) and strategically engage stakeholders, including end-users, key influencers, male partners, service providers in research and non-research determined activities to inform and advance emerging HIV prevention products through MATRIX.
  3. To engage with Product Developers and identify mechanisms through which D2D may inform ongoing development or modification of product delivery or attributes to enhance acceptability among women and key stakeholders.
  4. To conduct a landscape analysis of current SBR to synthesize data on the needs, preferences and product-related behaviors of key end-users and influential stakeholder groups.

Contributions to prevention of HIV and responding to the needs of AGYW

MATRIX is focused on addressing the unmet needs of AGYW through the prioritization of products which extend the dosing intervals of proven antiretroviral agents (CAB implant and injectable) and which could thereby reduce participant burden and potentially increase adherence and persistence. MATRIX will advance novel on demand products which do not require use of ARVs (Griffithsin fast dissolving insert) or use of combinations of ARVs which potentially provide several days of protection after a single application (Tenofovir Alafenamide/Elvitegravir FDI). For women who want a monthly product without the use of a ring or injection, the extended-release film is an innovative product poised to provide a month of protection from a single application. The unmet needs of women who desire both contraception and HIV prevention but who want to avoid contraceptive hormones and ARVs, could be fulfilled with the nonhormonal non-ARV ring developed by Oak Crest. The integration of end-user feedback is woven into every component of MATRIX from gaining input on product design, acceptability of the product format and safety and acceptability of the products within the proposed end-user populations.

Target population

PZAT is committed to working with the Government of Zimbabwe and various stakeholders focusing on advancing products that address the unmet needs of adolescent girls and young women (AGYW), pregnant and breastfeeding women (PBFW), and female sex workers (FSW); and enhancing early R&D capacity in SSA for sustainability in the region.

Current activities

PZAT is committed to the development of a “rapid response network,” creation of a D2D dashboard, ongoing PD consultations, and a landscape analysis. MATRIX is the first program of its kind which incorporates end-user’s perspective early in product development by providing rapid feedback to ensure that the products being developed will be acceptable for the AGYW in Sub-Saharan Africa.

Share
3

Related posts

22nd April 2019

Formative evaluation for the roll-out of long-acting pre-exposure prophylaxis


Read more
22nd April 2019

CASPR


Read more
22nd April 2019

WILD4LIFE HEALTH


Read more

Interested in one of our programmes or just need to get more information?


Send a message
Facebook icon Twitter icon

Website - shortcuts


  • Home
  • About Us
  • Our Team
  • Board of Directors
  • Programmes
  • Get involved
  • Careers
  • Resources
  • Contact
  • Sitemap

Quick contact with office



+263 8677 175 026

admin@pzat.org

© 2019 - 2022 Pangaea Zimbabwe AIDS Trust. All Rights Reserved. Akoiweb for Web Design Zimbabwe